Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
Alessandra MangiaRuggero LosappioGiovanni CenderelloDomenico PotenzaMichele MazzolaGiulio De StefanoNatalia TerreniMassimiliano CopettiNicola MinervaValeria PiazzolaDonato BaccaVincenzo PalmieriFernando SogariRosanna SantoroPublished in: PloS one (2018)
Our real-world results validate the efficacy of current GT3 IFN-free regimens suggesting that, among patients with severe disease, Peg/IFN/RBV experience and NS5A associated RASs are predictors of relapse. Their relevance can be expected to decline with the use of SOF/VEL. (250).